Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240825 | 0.95 | POLB (0.73) | POLBNPC1RAB9AARELANE | |
| SCHEMBL13879569 | 0.84 | POLB (0.54) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL13879542 | 0.82 | POLB (0.65) | POLBNPC1RAB9AARELANE | |
| SCHEMBL13879402 | 0.82 | AR (0.53) | POLBNPC1RAB9AARMEN1 | |
| SCHEMBL3960645 | 0.79 | POLB (0.71) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL13879525 | 0.79 | POLB (0.65) | POLBNPC1RAB9AARELANE | |
| SCHEMBL11461814 | 0.79 | AR (0.64) | POLBARELANEMEN1KMT2A | |
| SCHEMBL3956206 | 0.78 | POLB (0.73) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL242688 | 0.74 | POLB (0.68) | POLBNPC1RAB9AARMEN1 | |
| SCHEMBL242108 | 0.74 | POLB (0.72) | POLBNPC1RAB9AARELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | POLB 171/4885NPC1 680/4885RAB9A 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.